Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Inflaming the microenvironment of colorectal cancer to enable immunotherapy

Obiettivo

Microsatellite-stable colorectal cancer (MSS CRC) accounts for 85–90% of CRCs and remains largely resistant to immune checkpoint blockade (ICB), one of the most transformative advances in oncology. Consequently, the majority of patients with advanced CRC cannot benefit from immunotherapy, representing a major unmet clinical need. INFLAME-TME proposes a novel strategy to overcome this limitation by converting immunologically “cold” MSS tumors into ICB-responsive lesions through targeted induction of tumor-intrinsic immunogenic stress.
Building on discoveries from the ERC AdG PLASTICAN, we identified a previously unrecognized target that is responsible for mitotic spindle assembly while its downregulation causes chromosome missegregation, micronucleus formation, and activation of the cGAS/STING innate immune pathway. In preclinical models of MSS CRC, depletion induces strong CD8⁺ T cell infiltration and sensitizes tumors to ICB. To translate this discovery into a therapeutic strategy, we developed a targeted RNA-based approach aiming to impair tumor cell division while triggering innate immune activation within the tumor microenvironment. INFLAME-TME will assess the technical feasibility and translational potential of this strategy. Key objectives include validating mitotic disruption and cGAS/STING activation, evaluating ICB sensitization, and defining the intellectual property, regulatory, and commercialization paths for further development.
If successful, INFLAME-TME will establish a new paradigm in cancer immunotherapy where targeted RNA delivery induces tumor-intrinsic immunogenicity to overcome ICB resistance. Beyond CRC, this concept could open opportunities for RNA-based immunomodulatory therapies across diverse immunotherapy-resistant malignancies.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2026-POC

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS STIFTUNG
Contributo netto dell'UE
€ 150 000,00
Indirizzo
PAUL EHRLICH STRASSE 42-44
60596 FRANKFURT
Germania
Regione
Berlin Berlin Berlin
Tipo di attività
Research Organisations
Collegamenti
Costo totale
Nessun dato

Beneficiari (1)